Pay in 4 interest-free payments of $7.30 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Introducing Hot Shots, a series that examines how Ozempic and other GLP-1 drugs have transformed the way we think about our bodies, weight loss, and wellness
Similar patterns appeared in other obesity-related cancers: Non-small cell lung cancer: progression to Stage IV roughly 10% versus 22% Colorectal cancer: statistically significant reduction in progression Hepatocellular (liver) cancer: signal in the same direction A separate JAMA Oncology study by Dai and colleagues (2025), distinct from the Cleveland Clinic ASCO analysis, found about a 17% lower overall cancer incidence (hazard ratio approximately 0.83) in adults with obesity who used GLP-1 receptor agonists, with most of the signal coming from skin cancers and obesity-related solid tumors
Bibcode:2012CSRev..41.1499F
doi: 10.1016/S0022-2275(20)41151-4 61 GalsgaardKDPedersenJKnopFKHolstJJWewer AlbrechtsenNJ
GLP-1 medication use also led to nearly a 4x higher likelihood of developing gastroparesis, or stomach paralysis, versus bupropion-naltrexone use, according to the study
The half-life of GLP-1 in the body is 7 days
